Time-dependently slow-released multiple-drug eluting external sheath for efficient long-term inhibition of saphenous vein graft failure.
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
/ administration & dosage
Animals
Coronary Artery Bypass
Drug Delivery Systems
Everolimus
/ administration & dosage
Graft Rejection
/ prevention & control
Immunosuppressive Agents
/ administration & dosage
Rabbits
Saphenous Vein
/ transplantation
Simvastatin
/ administration & dosage
Biodegradable
Combination therapy
Sustained release
Vascular external sheath
Vein graft failure
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
10 01 2019
10 01 2019
Historique:
received:
15
09
2018
revised:
19
11
2018
accepted:
01
12
2018
pubmed:
7
12
2018
medline:
20
3
2020
entrez:
7
12
2018
Statut:
ppublish
Résumé
Coronary artery bypass graft surgery (CABG) is an effective therapeutic method for coronary artery disease. Great saphenous vein is the predominant graft due to the accessibility, sufficient length and suitable size matching with coronary artery. However, saphenous vein graft failure (SVGF) always restrict the long-term success of CABG. In this study, a complex external sheath was prepared using multi-channel and coaxial electrospinning techniques. The sheath can slowly release fasudil dihydrochloride (100% at 63 days), everolimus (100% at 84 days) and simvastatin (31.87 ± 1.55% at 20 weeks) to match the time-dependent pathological changes of SVGF through a cocktail pattern. In 16 weeks animal experiments, drug loaded sheath exhibited significantly greater efficacy in inhibiting neointima formation and ensuring graft patency than bare vein graft and empty sheath. Under the joint action of mechanical restriction of the sheath and the synergistic effect of loaded fasudil dihydrochloride and everolimus, the endothelium damage and the proliferation/migration of smooth muscle cells, which were thought to be the early cause of graft failure, could be efficiently alleviated. Moreover, the long-term patency could be expected due to the inhibition of atherosclerosis by the sustained released simvastatin.
Identifiants
pubmed: 30521829
pii: S0168-3659(18)30696-5
doi: 10.1016/j.jconrel.2018.12.001
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
84477-87-2
Everolimus
9HW64Q8G6G
Simvastatin
AGG2FN16EV
fasudil
Q0CH43PGXS
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
172-182Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.